# Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Source: https://onco.cc/trials/nct04851613/  
OnCo record `nct04851613` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Afuresertib in advanced solid tumours, run by Laekna Limited, active and no longer recruiting.

## Summary

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer is a phase 3 interventional study registered as NCT04851613 by Laekna Limited, with 256 participants enrolled, started 2022-02-18 and due to reach its primary completion in 2026-10-30. Interventions recorded: Afuresertib and Afuresertib/placebo.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04851613
- Phase: 3
- Setting: A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies
- Sponsor: Laekna Limited
- Enrolled: 256

## Sources

- ClinicalTrials.gov NCT04851613: https://clinicaltrials.gov/study/NCT04851613

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct04851613.json